Gandy Stephen J, Sudarshan Thiru A P, Sheppard Declan G, Allan Lynsay C, McLeay Trudy B, Houston J Graeme
Tayside Institute for Cardiovascular Research, Department of Clinical Radiology, Ninewells Hospital, Dundee, UK.
J Magn Reson Imaging. 2003 Oct;18(4):461-6. doi: 10.1002/jmri.10381.
To evaluate differences in the magnitude and time course of renal cortical contrast uptake in patients with minimal, moderate, and severe renal artery stenosis (RAS) using contrast-enhanced magnetic resonance renography (CE-MRR).
CE-MRR was performed on 56 patients with renovascular disease using a three-dimensional volume interpolated breath-hold examination (VIBE) perfusion sequence. After administration of 2 mL of contrast, nine sequential axial VIBE datasets were acquired: at baseline, 7, 14, 21, 45, 60, 120, 180, and 240 seconds. Aortic peak signal enhancement and cortical peak signal enhancement through the mid portion of each kidney was recorded, along with the time delay between each peak. Each renal artery was subsequently examined using three-dimensional contrast-enhanced MR angiography, and graded as being minimally (0%-30%), moderately (31%-70%), or severely (71%-100%) stenotic.
When the data were subdivided by RAS category, the cortical to aortic peak enhancement ratio (CAPR) reduced with increasing RAS. Further, the cortical to aortic time delay (CATD) increased with increasing RAS. These measurements were statistically significant between patients with minimal and moderate RAS compared to severe RAS CONCLUSION: CE-MRR can assist in the differentiation of patients with minimal or moderate RAS from those with severe RAS.
使用对比增强磁共振肾造影(CE-MRR)评估轻度、中度和重度肾动脉狭窄(RAS)患者肾皮质对比剂摄取的程度和时间过程差异。
对56例肾血管疾病患者采用三维容积内插屏气检查(VIBE)灌注序列进行CE-MRR检查。静脉注射2 mL对比剂后,采集9个连续的轴向VIBE数据集:基线、7、14、21、45、60、120、180和240秒时。记录主动脉峰值信号增强以及通过每个肾脏中部的皮质峰值信号增强,以及每个峰值之间的时间延迟。随后使用三维对比增强磁共振血管造影检查每条肾动脉,并将其分级为轻度(0%-30%)、中度(31%-70%)或重度(71%-100%)狭窄。
当数据按RAS类别细分时,皮质与主动脉峰值增强比(CAPR)随RAS程度增加而降低。此外,皮质与主动脉时间延迟(CATD)随RAS程度增加而增加。与重度RAS患者相比,轻度和中度RAS患者之间的这些测量结果具有统计学意义。结论:CE-MRR有助于区分轻度或中度RAS患者与重度RAS患者。